Biora Therapeutics Inc.
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
IPO Year: 2020
Exchange: NASDAQ
Website: https://www.bioratherapeutics.com
Biora Therapeutics Inc. Press Releases
Fastest customizable press release news feed in the world
Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth
Sale process will help enable next stage of product development Secures up to $10.25 million in new financing to support ongoing business operations SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. ("Biora" or the "Company"), a biotech company developing smart pill-based therapeutic platforms, today announced it has reached an agreement with certain of its prepetition creditors (the "Lenders") to provide financing to support a chapter 11 sale process, which will ultimately lead to a strengthened balance sheet and help enable it to launch its next stage of product development. To effectuate the transaction, the Company has filed a voluntary petition under chapter 11 o
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. The company will not host a conference call. "We've made much faster progress than anticipated developing a smaller BioJet device that is highly desired by pharma companies," said A
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host a webcast and conference call on Thursday, November 14, 2024, after the close of financial markets. Conference Call and Webcast InformationDate: Thursday, November 14, 2024Time: 4:30 PM Eastern time / 1:30 PM Pacific timeConference Call: Domestic 1-877-423-9813International 1-201-689-8573Conference ID 13749254Live Webcast: https://investors.bioratherapeutics.com/events-presentations A replay will
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 745,342 shares of the Company's common stock at an offering price of $4.025 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 745,342 shares of common stock. The warrants have an exercise price of $3.90 per share, will be exercisable upon issuance, and will expire five years following issuance. The closing
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today is sharing progress on its development of the BioJet™ Oral Delivery Platform, which is designed to replace injection with needle-free, oral delivery, at the 14th Annual Partnership in Drug Delivery (PODD) meeting in Boston, Massachusetts. "We have now demonstrated the ability to autonomously deliver to the small intestine in canine models with our smaller, 00-size BioJet device, a size that is desired by both patients and pharma companies," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "We have agreed with existing mega-cap p
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting
SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced that Adi Mohanty, CEO of Biora Therapeutics, will present on the company's 00-size BioJet™ device at the 14th Annual Partnership Opportunities in Drug Delivery (PODD) meeting, taking place in Boston, October 28–29, 2024. "As part of the development of our clinical-ready BioJet device, we were able to reduce its size from 000 to 00, while slightly increasing the payload capacity," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "Market research indicates a strong patient preference for a 00-size device, a preference that
Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium
SAN DIEGO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will present at the 19th Annual Peptide Therapeutics Symposium, taking place virtually and in person in La Jolla, California, October 22–23, 2024. Details of the presentation are as follows: Presentation Title:Empowering Peptide Self-Administration with Needle Free Smart CapsulesDate & Time:October 22, 2024, 2:30 PM – 3:00 PM PTPresenter:Sharat Singh, PhD, Head of Research, Biora Therapeutics The Peptide Therapeutics Symposium brings together world leaders in peptide research from academia and the biopharmaceuti
Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced an upcoming poster presentation at the American College of Gastroenterology (ACG) Annual Scientific Meeting, which will be held in Philadelphia, October 25–30, 2024. Biora's submission was awarded a Presidential Poster Award by the ACG Abstract Selection Committee. Each year less than 5% of accepted abstracts receive this distinction for high quality, novel, unique, and interesting research. Details of the presentation are as follows: Poster Number:P4275 Session Date:October 29, 2024 10:30 AM – 4:00 PM ET Presenting Author:Brian Feag
Biora Therapeutics Achieves ISO 13485 Certification
SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it has been awarded ISO 13485:2016 certification by TÜV SÜD America, demonstrating the company's commitment to compliance with the most rigorous global regulatory and quality standards. "We are proud of the robust systems our team has built, ensuring stringent control over development and manufacturing processes," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "This certification demonstrates our ongoing ability to meet exacting regulatory requirements as we continue to achieve clinical and developmental milestones
Biora Therapeutics Announces Positive Nasdaq Listing Decision
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced that the company has been granted an extension to regain compliance with Nasdaq listing requirements. "We shared with Nasdaq the upcoming company catalysts that we believe will drive significant value for shareholders, and we are pleased with their decision to grant us an extension to regain compliance," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "We look forward to continuing to achieve milestones in the development of our innovative NaviCap™ and BioJet™ therapeutics platforms." The Nasdaq Hearings Panel granted
Biora Therapeutics Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
SEC Form 4 filed by Director Athyrium Opportunities Iii Co-Invest 1 Lp
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
Officer Neumann Clarke covered exercise/tax liability with 26,629 shares, decreasing direct ownership by 5% to 465,564 units (SEC Form 4)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
Chief Financial Officer Desparbes Eric covered exercise/tax liability with 27,830 shares, decreasing direct ownership by 5% to 575,832 units (SEC Form 4)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
Chief Executive Officer Mohanty Aditya P. covered exercise/tax liability with 70,883 shares, decreasing direct ownership by 5% to 1,468,609 units (SEC Form 4)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
SEC Form 4 filed by Director Athyrium Opportunities Iii Co-Invest 1 Lp
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
SEC Form 4 filed by Director Athyrium Opportunities Iii Co-Invest 1 Lp
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
SEC Form 4 filed by Director Athyrium Opportunities Iii Co-Invest 1 Lp
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
Powell Lynne was granted 12,500 shares, increasing direct ownership by 69% to 30,746 units (SEC Form 4)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
Howe Jill Ann was granted 12,500 shares, increasing direct ownership by 64% to 31,916 units (SEC Form 4)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
Kotzin Brian L. was granted 12,500 shares, increasing direct ownership by 69% to 30,746 units (SEC Form 4)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
Biora Therapeutics Inc. SEC Filings
Biora Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Financial Statements and Exhibits
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
SEC Form 8-K filed by Biora Therapeutics Inc.
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
SEC Form 8-K filed by Biora Therapeutics Inc.
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
SEC Form 10-Q filed by Biora Therapeutics Inc.
10-Q - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
Biora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
Biora Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
SEC Form 424B5 filed by Biora Therapeutics Inc.
424B5 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
SEC Form 424B3 filed by Biora Therapeutics Inc.
424B3 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
SEC Form 424B3 filed by Biora Therapeutics Inc.
424B3 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
SEC Form 424B3 filed by Biora Therapeutics Inc.
424B3 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
Biora Therapeutics Inc. Leadership Updates
Live Leadership Updates
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer. Dr. Kelman has a proven track record of leading global biopharmaceutical development, clinical trials, and regulatory strategies. "Dr. Kelman is an outstanding addition to our team as we progress our programs into later stages of development and prepare to enter the clinic with the BT-600 program, which is designed to deliver our unique formulation of tofacitinib to the colon using our proprietary GItrac™ technology," said Adi Mohanty, Chief Executive Officer of Bio
Biora Therapeutics Appoints Dr. Bruce Sands as Chair of its Clinical Advisory Board
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutics, announced today the appointment of Dr. Bruce Sands as board chair of its Clinical Advisory Board for Inflammatory Bowel Disease (IBD), which also includes leading IBD researchers Dr. Geert D'Haens, Dr. Brian Feagan, and Dr. Séverine Vermeire. The clinical advisory board provides strategic guidance on clinical development of Biora's Targeted Therapeutics pipeline. "Targeted drug delivery to the large intestine has the potential to enable new therapeutic approaches, including combination therapy, for IBD patients," said Dr. Bruce Sands. "I'm pleased to
Biora Therapeutics Inc. Financials
Live finance-specific insights
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. The company will not host a conference call. "We've made much faster progress than anticipated developing a smaller BioJet device that is highly desired by pharma companies," said A
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host a webcast and conference call on Thursday, November 14, 2024, after the close of financial markets. Conference Call and Webcast InformationDate: Thursday, November 14, 2024Time: 4:30 PM Eastern time / 1:30 PM Pacific timeConference Call: Domestic 1-877-423-9813International 1-201-689-8573Conference ID 13749254Live Webcast: https://investors.bioratherapeutics.com/events-presentations A replay will
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from existing investors supported by BT-600 results and progress toward BioJet™ partnership Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. "Research shows that ulcerative colitis patients with higher drug exposur
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the second quarter ended June 30, 2024. Company management will host a webcast and conference call on Monday, August 12, 2024, after the close of financial markets. Conference Call and Webcast InformationDate:Monday, August 12, 2024Time:4:30 PM Eastern time / 1:30 PM Pacific timeConference Call:Domestic 1-877-423-9813 International 1-201-689-8573 Conference ID 13747616Call me for instant telephone accessLive Webcast:https://investors.bioratherapeutics.com/events-presenta
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented at DDW on May 19 Partnering process for the BioJet oral delivery platform is progressing well Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. "We were gratified to see the excellent int
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the first quarter ended March 31, 2024. The company's management will host a webcast and conference call on Wednesday, May 15, 2024, after the close of financial markets. Conference Call and Webcast Information Date: Wednesday, May 15, 2024 Time: 4:30 PM Eastern time / 1:30 PM Pacific time Conference Call: Domestic 1-877-423-9813 International 1-201-689-8573 Conference ID 13746163 Call me for instant telephone access Live Webcast: https://investors.bior
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood Remainder of BT-600 clinical trial progressing well and on schedule Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2023. "We are thrilled by t
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the fourth quarter and full year ended December 31, 2023. The company's management will host a webcast and conference call on Tuesday, March 26, 2024, after the close of financial markets. Conference Call and Webcast InformationDate:Tuesday, March 26, 2024Time:4:30 PM Eastern time / 1:30 PM Pacific timeConference Call:Domestic 1-877-423-9813 International 1-201-689-8573 Conference ID 13744533 Call me for instant telephone accessLive Webcast:https://investors.bio
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
NaviCap™ Targeted Oral Delivery platform advancing toward initiation of phase 1 clinical trial by year end Pharma collaborations accelerate for the BioJet™ Systemic Oral Delivery platform, which shows potential for liver-targeted delivery of large molecules Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2023. The company's management will host a webcast and conference call on Monday, November 13, 2023, after the close of financial markets at 4:30 PM Eastern time / 1:30 PM Pacific time. The live call may be accessed by dialing 1-877-423-9813 (domestic) or 1-201-689-8573 (international) and entering the conference code: 13741259. A live webcast will be available via the Investor Relations section of the company website, wit
Biora Therapeutics Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G filed by Biora Therapeutics Inc.
SC 13G - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
Amendment: SEC Form SC 13D/A filed by Biora Therapeutics Inc.
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
Amendment: SEC Form SC 13D/A filed by Biora Therapeutics Inc.
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SEC Form SC 13G filed by Biora Therapeutics Inc.
SC 13G - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
Amendment: SEC Form SC 13D/A filed by Biora Therapeutics Inc.
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
Amendment: SEC Form SC 13D/A filed by Biora Therapeutics Inc.
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SEC Form SC 13D/A filed by Biora Therapeutics Inc. (Amendment)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SEC Form SC 13G/A filed by Biora Therapeutics Inc. (Amendment)
SC 13G/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SEC Form SC 13D/A filed by Biora Therapeutics Inc. (Amendment)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SEC Form SC 13D/A filed by Biora Therapeutics Inc. (Amendment)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)